Hydroflumethiazide
A thiazide diuretic used to treat high blood pressure and edema by increasing urinary sodium and water excretion from the kidneys, reducing blood volume and relaxing blood vessel walls. It may be used alone or in combination with other antihypertensive agents for better blood pressure control. Monitoring of electrolytes, particularly potassium, is recommended during treatment.
Peso Molecular
331,3000 g/mol
LogP
0,40
TPSA
135,00 Ų
Regra dos 5 de Lipinski
Aprovado
Áreas Terapêuticas
Mecanismo de Ação
Provides essential ions for maintaining fluid balance, nerve conduction, muscle contraction, and acid-base homeostasis. Supplementation corrects electrolyte imbalances.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Provides essential ions for maintaining fluid balance, nerve conduction, muscle contraction, and acid-base homeostasis. Supplementation corrects electrolyte imbalances.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NCNS2(=O)=O
InChI
InChI=1S/C8H8F3N3O4S2/c9-8(10,11)4-1-5-7(2-6(4)19(12,15)16)20(17,18)14-3-13-5/h1-2,13-14H,3H2,(H2,12,15,16)
Molecular Formula
C8H8F3N3O4S2
HBD / HBA
3 / 10
Ligações Rotacionáveis
1
Átomos Pesados
20
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
A thiazide diuretic used to treat high blood pressure and edema by increasing urinary sodium and water excretion from the kidneys, reducing blood volume and relaxing blood vessel walls. It may be used alone or in combination with other antihypertensive agents for better blood pressure control. Monitoring of electrolytes, particularly potassium, is recommended during treatment.
Provides essential ions for maintaining fluid balance, nerve conduction, muscle contraction, and acid-base homeostasis. Supplementation corrects electrolyte imbalances.
Yes, Hydroflumethiazide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1763. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3647. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="hydroflumethiazide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/hydroflumethiazide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/hydroflumethiazide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/hydroflumethiazide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="hydroflumethiazide"></drugfyi-drug>